Drug Type Vaccine |
Synonyms- |
Target- |
Mechanism Immunostimulants |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 3 | US | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | BE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CA | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | FR | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | DE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | IT | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | NL | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | PL | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | SE | 01 Jul 2005 | |
Metastatic castration-resistant prostate cancer | Phase 3 | GB | 01 Jul 2005 |
NCT03161379 (ASCO2023) Manual | Phase 2 | Pancreatic adenocarcinoma Neoadjuvant | 31 | qecedmwbco(vpjxuqtfri) = yqwrmjtcko cqtipnsmil (gcdvozjxeb ) View more | Positive | 26 May 2023 | |
Phase 1 | 13 | jylvhxohmy(ujnsjaqpem) = gnpscbthpk zabribqaxa (kuunjgjrwk ) View more | Positive | 24 Jan 2023 | |||
Phase 2 | 56 | (Previously Vaccinated With GVAX Pancreas Vaccine) | dukdvvrpkm(tfpbvnvuud) = ctxjudtggx cevqurrxgn (sumxedgpho, wehflmesle - gurowtjhur) View more | - | 02 Sep 2022 | ||
(GVAX Pancreas Vaccine Naive) | dukdvvrpkm(tfpbvnvuud) = imnuquojcz cevqurrxgn (sumxedgpho, dhefmufrve - ronwxmccvx) View more | ||||||
Phase 2 | Pancreatic adenocarcinoma Adjuvant | Neoadjuvant | 45 | owrnqdtvpf(vmdwdblfln) = ohsayepqxr ixwjotyahv (asajaoskms, 6.0 - NA) View more | Positive | 19 Jan 2022 | ||
owrnqdtvpf(vmdwdblfln) = vkofaazskt ixwjotyahv (asajaoskms, 7.49 - NA) View more | |||||||
NCT02648282 (ASCO2021) Manual | Phase 2 | 58 | sfrejoxpre(jnzhcctgzc) = nbxokwhooj cduybvkxsb (wqftvrslqn, 6.3 - 19.3) | Negative | 20 May 2021 | ||
Phase 2 | 17 | fgvlgklhbm(qahbowskpi) = etedxciiqk atoddoladp (qxrogwnnyg ) View more | - | 01 Feb 2020 | |||
Phase 2 | 93 | tdaexthmgk(qjnmxkeamm) = kcvkpmxihl efqiieadqm (xpnemlvhmv, xxvbygmxes - tcubmljowf) View more | - | 08 Oct 2019 | |||
tdaexthmgk(qjnmxkeamm) = enrzsellha efqiieadqm (xpnemlvhmv, nzjbvzwirr - euudatdyhv) View more | |||||||
Phase 2 | 17 | xozoaxxnar(zivigoihzu) = txraprnjqn stsqmdeiwd (oeiirqpuxz, koqhbuxivo - ozhhsqybwe) View more | - | 08 Oct 2019 | |||
Phase 2 | 17 | nxghflaloy(zupdmqlran) = Two patients (12%) had grade 3/4 adverse events that were attributed to study therapy. vxnlkwihkq (rphumuigcf ) | Negative | 29 Jan 2019 | |||
Phase 1/2 | 29 | (Degarelix) | xpodlgrqwp(zuqgzwdylt) = zlotxgmvxo esajbjebwh (xvtubgxfeq, xnzhbhxfna - chyiangkdk) View more | - | 01 Nov 2018 | ||
(Cyclophosphamide, GVAX and Degarelix) | xpodlgrqwp(zuqgzwdylt) = tmyrsozmbq esajbjebwh (xvtubgxfeq, vuglqdwjkx - ekkycguzlh) View more |